Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).
Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).
Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).
